New drug could shield lung transplants from silent failure
NCT ID NCT06476132
First seen Jan 22, 2026 · Last updated May 24, 2026 · Updated 12 times
Summary
This study tests whether the drug belumosudil can prevent chronic lung allograft dysfunction (CLAD) in people who have had a lung transplant and show signs of early rejection or inflammation. About 234 participants will receive either belumosudil or a placebo for 52 weeks, alongside their usual anti-rejection medicines. The goal is to see if the drug can delay or stop CLAD, a serious condition that can lead to lung failure or the need for another transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cincinnati Children's Hospital Medical Center (Site #: 71017)
RECRUITINGCincinnati, Ohio, 45229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cleveland Clinic (Site #: 71101)
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Duke University (Site #: 71139)
RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins (Site #: 71119)
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NYU Langone Health (Site #: 71177)
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford University (Site #: 71141)
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Health Network/Toronto General Hospital (Site #: 71121)
RECRUITINGToronto, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, Los Angeles (Site #: 71123)
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Minnesota (Site 71151)
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania (Site #: 71111)
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt University Medical Center (Site #: 71174)
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University (Site #: 71157)
RECRUITINGSt Louis, Missouri, 63130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.